NYB (NYB Holdings) Interest Coverage: 0 (At Loss) (As of Sep. 2025)


What is NYB Holdings Interest Coverage?

NYB Holdings NYB Interest Coverage is 0 (At Loss) as of Sep. 2025.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. NYB Holdings's Operating Income for the six months ended in Sep. 2025 was $-3.35 Mil. NYB Holdings's Interest Expense for the six months ended in Sep. 2025 was $-0.03 Mil. did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for NYB Holdings's Interest Coverage or its related term are showing as below:


NYB's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 106.07
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

NYB Holdings  (NAS:NYB) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

NYB Holdings Interest Coverage Related Terms

NYB Holdings Interest Coverage Historical Data

* Premium members only.

The historical data trend for NYB Holdings's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

NYB Holdings Interest Coverage Chart

NYB Holdings Annual Data
Trend Sep24 Sep25
Interest Coverage
0.00 0.00

NYB Holdings Semi-Annual Data
Sep24 Sep25
Interest Coverage 0.00 0.00

NYB vs : Interest Coverage Comparison

For the Biotechnology subindustry, NYB Holdings's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NYB Holdings Interest Coverage vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NYB Holdings's Interest Coverage distribution charts can be found below:

* The bar in red indicates where NYB Holdings's Interest Coverage falls into.


NYB Holdings Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

NYB Holdings's Interest Coverage for the fiscal year that ended in Sep. 2025 is calculated as

Here, for the fiscal year that ended in Sep. 2025, NYB Holdings's Interest Expense was $-0.03 Mil. Its Operating Income was $-3.35 Mil. And its Long-Term Debt & Capital Lease Obligation was $1.71 Mil.

NYB Holdings did not have earnings to cover the interest expense.

NYB Holdings's Interest Coverage for the quarter that ended in Sep. 2025 is calculated as

Here, for the six months ended in Sep. 2025, NYB Holdings's Interest Expense was $-0.03 Mil. Its Operating Income was $-3.35 Mil. And its Long-Term Debt & Capital Lease Obligation was $1.71 Mil.

NYB Holdings did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.

Frequently Asked Questions Learn more about Interest Coverage →
What does a Interest Coverage of 0 (At Loss) mean?
NYB Holdings (NYB) has a Interest Coverage of 0 (At Loss) as of Sep. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on NYB Holdings and its competitors.
Is NYB Holdings' Interest Coverage too high?
NYB Holdings' current Interest Coverage is 0 (At Loss).
How does NYB Holdings' Interest Coverage compare to ?
NYB Holdings' Interest Coverage of 0 (At Loss) can be compared against companies in the Biotechnology industry. The industry median Interest Coverage is 106.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on NYB Holdings and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NYB Holdings's current Interest Coverage is 0 (At Loss). However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NYB Holdings stock overvalued right now?
NYB Holdings (NYB) has a current Interest Coverage of 0 (At Loss). The current Interest Coverage is 0 (At Loss). Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For NYB Holdings (NYB), the current Interest Coverage is 0 (At Loss) as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NYB Holdings Business Description

Comparable Companies
Address 456 Alexandra Road, No. 04-07, Fragrance Empire Building, Singapore, SGP, 119962
NYB Holdings Ltd, along with its subsidiaries, is a pre-clinical biopharmaceutical company engaged in the research and development of therapeutics and nutraceuticals derived from biodiversity, including tropical medicinal plants with a history of traditional use. It focuses on discovering and developing natural compounds for applications in oncology and other chronic diseases, and also offers a consumer nutraceutical product line.